Dyne Therapeutics Inc. (NASDAQ: DYN) stock fell -0.86% on Friday to $9.26 against a previous-day closing price of $9.34. With 1.34 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.51 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $9.50 whereas the lowest price it dropped to was $8.59. The 52-week range on DYN shows that it touched its highest point at $15.60 and its lowest point at $8.04 during that stretch. It currently has a 1-year price target of $29.50. Beta for the stock currently stands at 0.18.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DYN was down-trending over the past week, with a drop of -15.66%, but this was down by -12.31% over a month. Three-month performance dropped to -23.47% while six-month performance fell -27.94%. The stock lost -35.61% in the past year, while it has lost -20.10% so far this year. A look at the trailing 12-month EPS for DYN yields -3.40 with Next year EPS estimates of -3.12. For the next quarter, that number is -0.83. This implies an EPS growth rate of -10.30% for this year and 10.10% for next year.
Float and Shares Shorts:
At present, 61.02 million DYN shares are outstanding with a float of 60.34 million shares on hand for trading. On Aug 30, 2023, short shares totaled 5.63 million, which was 9.22% higher than short shares on Jul 30, 2023. In addition to Mr. Joshua T. Brumm as the firm’s CEO, Pres & Director, Ms. Susanna Gatti High M.B.A. serves as its Chief Operating Officer.
Through their ownership of 104.97% of DYN’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 38.33% of DYN, in contrast to 23.10% held by mutual funds. Shares owned by individuals account for 13.15%. As the largest shareholder in DYN with 4.64% of the stake, BlackRock Fund Advisors holds 2,833,181 shares worth 2,833,181. A second-largest stockholder of DYN, Citadel Advisors LLC, holds 2,706,003 shares, controlling over 4.43% of the firm’s shares. Deep Track Capital LP is the third largest shareholder in DYN, holding 2,499,912 shares or 4.10% stake. With a 2.38% stake in DYN, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 1,453,532 shares are owned by the mutual fund manager. The SPDR S&P Biotech ETF, which owns about 1.66% of DYN stock, is the second-largest Mutual Fund holder. It holds 1,012,097 shares valued at 11.54 million. iShares Russell 2000 ETF holds 1.56% of the stake in DYN, owning 949,361 shares worth 10.82 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, DYN reported revenue of $0.00 and operating income of -$52.76M. The EBITDA in the recently reported quarter was -$52.30M and diluted EPS was -$1.01.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DYN since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With DYN analysts setting a high price target of $47.00 and a low target of $20.00, the average target price over the next 12 months is $29.50. Based on these targets, DYN could surge 407.56% to reach the target high and rise by 115.98% to reach the target low. Reaching the average price target will result in a growth of 218.57% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded DYN stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 15 while that of sell transactions has risen to 38 over the past year. The total number of shares bought during that period was 2,742,192 while 716,610 shares were sold.